A Comprehensive Pan-Cancer Analysis of 33 Human Cancers Reveals the Immunotherapeutic Value of Opa interacting protein 5

Background: In previous research, the potential significance of the interaction between Opa interacting protein 5 (OIP5) and tumor immunotherapy has been documented. Nevertheless, a comprehensive understanding of the therapeutic value of this interaction remains lacking. Therefore, the objective of our study was to investigate the correlation between OIP5 and cancer immunotherapy in a total of 33 human malignancies Methods: : The data on the clinical characteristics and gene expression of 33 types of human cancers were extracted from The Cancer Genome Atlas database. The immunotherapy groups, which consist of GSE67501, GSE78220, and IMvigor210, were obtained from the Gene Expression Omnibus database. We also evaluated the prognostic significance of OIP5 by analyzing the clinical parameters related to tumor stage. Through single-sample gene set enrichment analysis, we examined the activity of OIP5 to illustrate the disparity between the protein expression level and transcriptome. In order to enhance our comprehension of the role played by OIP5 in the immunotherapy of human cancers, we investigated its association with the tumor microenvironment and its correlation with immune processes/elements such as the infiltration of immune cells, immune stimulants, immune inhibitors, and the major histocompatibility complex. We also conducted research to explore the relevant pathways that are linked to the signaling of OIP5 in cancer. Additionally, we explored the correlation between OIP5 and two biomarkers of immunotherapy, namely tumor mutational burden and microsatellite instability. Lastly, we examined the relationship between OIP5 and the response to immunotherapy using the three independent immunotherapy groups mentioned earlier. Results: : OIP5 was significant associated with tumor stage (9/21) in the studied human cancers and revealed potential prognostic value for predicting patient survival. Consistency has been observed between OIP5 activity in some cancers (21/33). Generally, OIP5 displayed a strong correlation with immune cell infiltration, immune modulators, and immunotherapeutic markers. Moreover, overexpression of OIP5 was markedly related to immune-relevant pathways. What’s more, significantly positive correlation was observed between OIP5 and the immunotherapeutic response in cohorts of GSE78220. Conclusions: : This study provided evidence regarding the function of OIP5 and its role in clinical treatment by investigating the immunotherapeutic value of OIP5 in 33 human cancers. However, the current results are preliminary and require further verification for the reason of adopting a bioinformatics approach.